{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:50:43Z","timestamp":1777593043014,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"publisher","award":["ST.C310.17.009"],"award-info":[{"award-number":["ST.C310.17.009"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.biopha.2021.111773","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T01:34:03Z","timestamp":1622252043000},"page":"111773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Metformin has no impact on nitric oxide production in patients with pre-diabetes"],"prefix":"10.1016","volume":"140","author":[{"given":"Edyta","family":"Sutkowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadetta","family":"Ka\u0142u\u017ca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Sutkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Wi\u015bniewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej Gamian","family":"Prof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.111773_bib1","doi-asserted-by":"crossref","unstructured":"UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet 1998; 352: 854\u2013865.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"10.1016\/j.biopha.2021.111773_bib2","doi-asserted-by":"crossref","unstructured":"Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention, Diabetes Care 2002; 25(12): 2165\u20132171.","DOI":"10.2337\/diacare.25.12.2165"},{"key":"10.1016\/j.biopha.2021.111773_bib3","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2337\/dc18-2356","article-title":"Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: the CODYCE Multicenter Prospective Study","volume":"42","author":"Sardu","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2021.111773_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2796.2004.01420.x","article-title":"Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial","volume":"257","author":"De Jager","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.biopha.2021.111773_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.diabres.2008.02.006","article-title":"The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients","volume":"81","author":"Ersoy","year":"2008","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2021.111773_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.vph.2015.09.003","article-title":"Oxidative stress in chronic vascular disease: from prediction to prevention","volume":"74","author":"Santilli","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111773_bib7","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/ndt\/gft022","article-title":"Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy","volume":"28","author":"Aminzadeh","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biopha.2021.111773_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-019-0931-0","article-title":"Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin","volume":"18","author":"Sardu","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2021.111773_bib9","doi-asserted-by":"crossref","first-page":"31629","DOI":"10.1074\/jbc.M212831200","article-title":"Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells","volume":"278","author":"Morrow","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2021.111773_bib10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2337\/diabetes.55.02.06.db05-1064","article-title":"Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase","volume":"55","author":"Davis","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2021.111773_bib11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3389\/fphys.2018.01857","article-title":"Therapeutic options targeting oxidative stress, mitochondrial dysfunction and inflammation to hinder the progression of vascular complications of diabetes","volume":"9","author":"Teodoro","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2021.111773_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2337\/diabetes.53.3.701","article-title":"Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment","volume":"53","author":"Ceriello","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2021.111773_bib13","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/eurheartj\/eht149","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I","volume":"34","author":"Paneni","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2021.111773_bib14","first-page":"2216","article-title":"Endothelial dysfunction - a major mediator of diabetic vascular disease","volume":"2013","author":"Sena","year":"1832","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2021.111773_bib15","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.2337\/db09-1772","article-title":"Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy","volume":"59","author":"Tessari","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2021.111773_bib16","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1210\/jc.2010-1170","article-title":"TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome","volume":"96","author":"Stanley","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2021.111773_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/ar3874","article-title":"Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance","volume":"14","author":"Stagakis","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2021.111773_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/792393","article-title":"Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus","volume":"2010","author":"van den Oever","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2021.111773_bib19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2174\/157016112803520936","article-title":"Dysglycemia and abdominal obesity","volume":"10","author":"Standl","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111773_bib20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/CIRCRESAHA.118.311912","article-title":"The vasculature in prediabetes","volume":"122","author":"Wasserman","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2021.111773_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.pharmthera.2010.04.009","article-title":"Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus","volume":"127","author":"Toda","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2021.111773_bib22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/ATVBAHA.113.301938","article-title":"Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5' adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor \u03b4 pathway","volume":"34","author":"Cheang","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2021.111773_bib23","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1016\/j.lfs.2005.05.022","article-title":"Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression","volume":"77","author":"Sartoretto","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2021.111773_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1476-5381.2011.01230.x","article-title":"Metformin restores endothelial function in aorta of diabetic rats","volume":"163","author":"Sena","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111773_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/147323001204000232","article-title":"Relationship between endothelial nitric oxide synthase, insulin resistance and macrovascular disease in patients with acute myocardial infarction","volume":"40","author":"Li","year":"2012","journal-title":"J. Int. Med. Res."},{"issue":"2020","key":"10.1016\/j.biopha.2021.111773_bib26","first-page":"255","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2021.111773_bib27","doi-asserted-by":"crossref","unstructured":"G. Montalescot, U.Sechtem, S. Achenbach, F. Andreotti, C. Arden, A. Budaj, R. Bugiardini, F. Crea, T. Cuisset, C. Di Mario, J.R. Ferreira, B.J. Gersh, A.K. Gitt, J.S. Hulot, N. Marx, L.H. Opie, M. Pfisterer, E. Prescott, F. Ruschitzka, M. Sabat\u00e9, R. Senior, D.P. Taggart, E.E. van der Wall, C.J. Vrints; ESC Committee for Practice Guidelines: J.L.Zamorano, S. Achenbach, H. Baumgartner, J.J. Bax, H. Bueno, V. Dean, C. Deaton, C. Erol, R. Fagard, R. Ferrari, D. Hasdai, A.W. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M.F. Piepoli, P. Ponikowski, P.A. Sirnes, J.L. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology, Eur Heart J. 34 (2013) 2949\u20133003. doi: \u300810.1093\/eurheartj\/eht296\u3009. Epub 2013 Aug 30.","DOI":"10.15829\/1560-4071-2014-7-7-79"},{"key":"10.1016\/j.biopha.2021.111773_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3994","article-title":"A novel mass spectrometry-based method for simultaneous determination of asymmetric and symmetric dimethylarginine, l-arginine and l-citrulline optimized for LC-MS-TOF and LC-MS\/MS","volume":"31","author":"Wi\u015bniewski","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.biopha.2021.111773_bib29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2021.111773_bib30","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1210\/en.2005-1433","article-title":"Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis","volume":"147","author":"Yang","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2021.111773_bib31","doi-asserted-by":"crossref","first-page":"43940","DOI":"10.1074\/jbc.M404421200","article-title":"Activation of the AMP-activated protein kinase by the antidiabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species","volume":"279","author":"Zou","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2021.111773_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2337\/diacare.27.1.41","article-title":"Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes","volume":"27","author":"Lawrence","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2021.111773_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2796.2004.01420.x","article-title":"Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial","volume":"257","author":"De Jager","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.biopha.2021.111773_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1464-5491.1991.tb01610.x","article-title":"Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients","author":"Grant","year":"1991","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2021.111773_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2337\/diacare.16.4.621","article-title":"Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups","volume":"16","author":"Nagi","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2021.111773_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diacare.19.1.64","article-title":"The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes","volume":"19","author":"Grant","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2021.111773_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2337\/diabetes.51.1.189","article-title":"The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation","volume":"51","author":"Standeven","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2021.111773_bib38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1530\/eje.1.01910","article-title":"Metformin administration improves endothelial function in women with polycystic ovary syndrome","volume":"152","author":"Diamanti-Kandarakis","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.biopha.2021.111773_bib39","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2337\/diabetes.54.5.1566","article-title":"Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance","volume":"54","author":"Haffner","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2021.111773_bib40","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1210\/jc.2002-021688","article-title":"Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome","volume":"88","author":"Morin-Papunen","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2021.111773_bib41","first-page":"620","article-title":"Citrulline and the gut","volume":"10","author":"Curis","year":"2007","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care."},{"key":"10.1016\/j.biopha.2021.111773_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.chroma.2005.05.009","article-title":"Determination of citrulline in watermelon rind","volume":"1078","author":"Rimando","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.biopha.2021.111773_bib43","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1053\/gast.2000.20227","article-title":"Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans","volume":"119","author":"Crenn","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2021.111773_bib44","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.biopha.2021.111773_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/07853890.2010.549144","article-title":"Disposition of metformin: variability due to polymorphisms of organic cation transporters","volume":"44","author":"Zolk","year":"2012","journal-title":"Ann. Med."},{"key":"10.1016\/j.biopha.2021.111773_bib46","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.bcp.2006.08.020","article-title":"Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin","volume":"72","author":"Mithieux","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111773_bib47","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature15766","article-title":"Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota [published correction appears in Nature]","volume":"528","author":"Forslund","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2021.111773_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: an update","volume":"137","author":"Kirpichnikov","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2021.111773_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial","volume":"103","author":"Garber","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biopha.2021.111773_bib50","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.2337\/db13-1367","article-title":"Metformin pharmacogenomics: current status and future directions","volume":"63","author":"Pawlyk","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2021.111773_bib51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s13300-020-00761-w","article-title":"Metformin delays the development of atherosclerosis in type 1 diabetes mellitus via the methylglyoxal pathway","volume":"11","author":"Liu","year":"2020","journal-title":"Diabetes Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221005552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221005552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:11:27Z","timestamp":1774530687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221005552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":51,"alternative-id":["S0753332221005552"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111773","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-47562\/v1","asserted-by":"object"}]},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin has no impact on nitric oxide production in patients with pre-diabetes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111773"}}